Baseline patient, disease, and transplant characteristics for all study patients, and for long-term vs short-term survivors
| . | All study patients∗ . | Disease-free and alive at 2 years . | Progression and/or death at 2 years . | P value . |
|---|---|---|---|---|
| (N=335) . | (N=142) . | (N=183) . | ||
| Age at transplant, y | ||||
| Median (range) | 48 (18-72) | 45 (18-72) | 52 (20-70) | .086 |
| Age at transplant, n (%) | ||||
| <55 y | 206 (61.49%) | 95 (66.90%) | 105 (57.38%) | .086 |
| ≥55 y | 129 (38.51%) | 47 (33.10%) | 78 (42.62%) | |
| Gender, n (%) | ||||
| Male | 195 (58.21%) | 82 (57.75%) | 105 (57.38%) | 1.000 |
| Female | 140 (41.79%) | 60 (42.25%) | 78 (42.62%) | |
| Race, n (%) | ||||
| Asian | 22 (6.71%) | 9 (6.47%) | 12 (6.70%) | |
| Black | 69 (21.04%) | 35 (25.18%) | 32 (17.88%) | .374 |
| Hispanic | 72 (21.95%) | 32 (23.02%) | 39 (21.79%) | |
| White | 165 (50.30%) | 63 (45.32%) | 96 (53.63%) | |
| Disease subtype, n (%) | ||||
| AML/MDS | 195 (58.21%) | 79 (55.63%) | 112 (61.20%) | |
| ALL | 55 (16.42%) | 21 (14.79%) | 32 (17.49%) | .115 |
| MPNs | 37 (11.04%) | 22 (15.49%) | 13 (7.10%) | |
| Lymphoid malignancies | 48 (14.33%) | 20 (14.08%) | 26 (14.21%) | |
| Time from diagnosis to transplant, n (%) | ||||
| <6 mo | 90 (26.87%) | 38 (26.76%) | 51 (27.87%) | .749 |
| 6-12 mo | 80 (50.75%) | 37 (26.06%) | 41 (22.40%) | |
| >12 mo | 165 (49.25%) | 67 (47.18%) | 91 (49.73%) | |
| Period of transplant, n (%) | ||||
| Transplant during 2009 to 2012 | 68 (20.30%) | 29 (20.42%) | 38 (20.77%) | |
| Transplant during 2013 to 2016 | 158 (47.16%) | 69 (48.59%) | 87 (47.54%) | .989 |
| Transplant during 2017 to 2019 | 109 (32.54%) | 44 (30.99%) | 58 (31.69%) | |
| KPS at transplant, n (%) | ||||
| KPS 90-100 | 206 (68.21%) | 92 (70.23%) | 107 (66.05%) | .454 |
| KPS < 90 | 96 (31.79%) | 39 (29.77%) | 55 (33.95%) | |
| DRI, n (%) | ||||
| Low/intermediate DRI | 189 (59.06%) | 99 (72.79%) | 82 (47.13%) | <.0001 |
| High/very high DRI | 131 (40.94%) | 37 (27.21%) | 92 (52.87%) | |
| HCT-CI, n (%) | ||||
| HCT-CI ≤ 3 | 217 (64.78%) | 99 (69.72%) | 112 (61.20%) | .128 |
| HCT-CI > 3 | 118 (35.22%) | 43 (30.28%) | 71 (38.80%) | |
| Stem cell source, n (%) | ||||
| Peripheral blood | 53 (15.82%) | 18 (12.68%) | 32 (17.49%) | .279 |
| Bone marrow | 282 (84.18%) | 124 (87.32%) | 151 (82.51%) | |
| Conditioning regimen, n (%) | ||||
| Reduced intensity | 297 (88.66%) | 125 (88.03%) | 164 (89.62%) | .723 |
| Myeloablative | 38 (11.34%) | 17 (11.97%) | 19 (10.38%) | |
| Patient-donor CMV, n (%) | ||||
| Seropositive-seropositive | 185 (64.01%) | 77 (65.81%) | 102 (61.82%) | .531 |
| Seropositive-seronegative | 104 (35.99%) | 40 (34.19%) | 63 (38.18%) | |
| Donor age, n (%) | ||||
| <35 y | 168 (50.15%) | 67 (47.18%) | 96 (52.46%) | .372 |
| ≥35 y | 167 (49.85%) | 75 (52.82%) | 87 (47.54%) | |
| Donor/recipient gender, n (%) | ||||
| Male/male | 125 (37.31%) | 50 (35.21%) | 69 (37.70%) | |
| Female/female | 60 (17.91%) | 29 (20.42%) | 30 (16.39%) | .611 |
| Male/female | 80 (23.88%) | 31 (21.83%) | 48 (26.23%) | |
| Female/male | 70 (20.90%) | 32 (22.54%) | 36 (19.67%) | |
| Donor/recipient relationship, n (%) | ||||
| Parent/child | 36 (10.75%) | 15 (10.56%) | 20 (10.93%) | |
| Sibling/sibling | 132 (39.40%) | 62 (43.66%) | 63 (34.43%) | .192 |
| Child/parent | 164 (48.96%) | 65 (45.78%) | 97 (53.00%) | |
| Other | 3 (0.90%) | 0 | 3 (1.64%) | |
| Anti-HLA antibody, n (%) | ||||
| No DSA | 240 (71.64%) | 105 (73.95%) | 128 (69.95%) | |
| Anti HLA class I Ab | 42 (12.54%) | 16 (11.27%) | 24 (13.11%) | .801 |
| Anti HLA class II Ab | 25 (7.46%) | 9 (6.34%) | 16 (8.74%) | |
| Anti HLA class I and II Ab | 28 (8.36%) | 12 (8.45%) | 15 (8.20%) | |
| Acute GVHD grades 2-4, n (%) | ||||
| No | 191 (57.01%) | 90 (63.38%) | 96 (52.46%) | .055 |
| Yes | 144 (42.99%) | 52 (36.62%) | 87 (47.54%) | |
| Chronic GVHD, n (%) | ||||
| No | 290 (86.57%) | 114 (80.28%) | 167 (91.26%) | .005 |
| Yes | 45 (13.43%) | 28 (19.72%) | 16 (8.74%) |
| . | All study patients∗ . | Disease-free and alive at 2 years . | Progression and/or death at 2 years . | P value . |
|---|---|---|---|---|
| (N=335) . | (N=142) . | (N=183) . | ||
| Age at transplant, y | ||||
| Median (range) | 48 (18-72) | 45 (18-72) | 52 (20-70) | .086 |
| Age at transplant, n (%) | ||||
| <55 y | 206 (61.49%) | 95 (66.90%) | 105 (57.38%) | .086 |
| ≥55 y | 129 (38.51%) | 47 (33.10%) | 78 (42.62%) | |
| Gender, n (%) | ||||
| Male | 195 (58.21%) | 82 (57.75%) | 105 (57.38%) | 1.000 |
| Female | 140 (41.79%) | 60 (42.25%) | 78 (42.62%) | |
| Race, n (%) | ||||
| Asian | 22 (6.71%) | 9 (6.47%) | 12 (6.70%) | |
| Black | 69 (21.04%) | 35 (25.18%) | 32 (17.88%) | .374 |
| Hispanic | 72 (21.95%) | 32 (23.02%) | 39 (21.79%) | |
| White | 165 (50.30%) | 63 (45.32%) | 96 (53.63%) | |
| Disease subtype, n (%) | ||||
| AML/MDS | 195 (58.21%) | 79 (55.63%) | 112 (61.20%) | |
| ALL | 55 (16.42%) | 21 (14.79%) | 32 (17.49%) | .115 |
| MPNs | 37 (11.04%) | 22 (15.49%) | 13 (7.10%) | |
| Lymphoid malignancies | 48 (14.33%) | 20 (14.08%) | 26 (14.21%) | |
| Time from diagnosis to transplant, n (%) | ||||
| <6 mo | 90 (26.87%) | 38 (26.76%) | 51 (27.87%) | .749 |
| 6-12 mo | 80 (50.75%) | 37 (26.06%) | 41 (22.40%) | |
| >12 mo | 165 (49.25%) | 67 (47.18%) | 91 (49.73%) | |
| Period of transplant, n (%) | ||||
| Transplant during 2009 to 2012 | 68 (20.30%) | 29 (20.42%) | 38 (20.77%) | |
| Transplant during 2013 to 2016 | 158 (47.16%) | 69 (48.59%) | 87 (47.54%) | .989 |
| Transplant during 2017 to 2019 | 109 (32.54%) | 44 (30.99%) | 58 (31.69%) | |
| KPS at transplant, n (%) | ||||
| KPS 90-100 | 206 (68.21%) | 92 (70.23%) | 107 (66.05%) | .454 |
| KPS < 90 | 96 (31.79%) | 39 (29.77%) | 55 (33.95%) | |
| DRI, n (%) | ||||
| Low/intermediate DRI | 189 (59.06%) | 99 (72.79%) | 82 (47.13%) | <.0001 |
| High/very high DRI | 131 (40.94%) | 37 (27.21%) | 92 (52.87%) | |
| HCT-CI, n (%) | ||||
| HCT-CI ≤ 3 | 217 (64.78%) | 99 (69.72%) | 112 (61.20%) | .128 |
| HCT-CI > 3 | 118 (35.22%) | 43 (30.28%) | 71 (38.80%) | |
| Stem cell source, n (%) | ||||
| Peripheral blood | 53 (15.82%) | 18 (12.68%) | 32 (17.49%) | .279 |
| Bone marrow | 282 (84.18%) | 124 (87.32%) | 151 (82.51%) | |
| Conditioning regimen, n (%) | ||||
| Reduced intensity | 297 (88.66%) | 125 (88.03%) | 164 (89.62%) | .723 |
| Myeloablative | 38 (11.34%) | 17 (11.97%) | 19 (10.38%) | |
| Patient-donor CMV, n (%) | ||||
| Seropositive-seropositive | 185 (64.01%) | 77 (65.81%) | 102 (61.82%) | .531 |
| Seropositive-seronegative | 104 (35.99%) | 40 (34.19%) | 63 (38.18%) | |
| Donor age, n (%) | ||||
| <35 y | 168 (50.15%) | 67 (47.18%) | 96 (52.46%) | .372 |
| ≥35 y | 167 (49.85%) | 75 (52.82%) | 87 (47.54%) | |
| Donor/recipient gender, n (%) | ||||
| Male/male | 125 (37.31%) | 50 (35.21%) | 69 (37.70%) | |
| Female/female | 60 (17.91%) | 29 (20.42%) | 30 (16.39%) | .611 |
| Male/female | 80 (23.88%) | 31 (21.83%) | 48 (26.23%) | |
| Female/male | 70 (20.90%) | 32 (22.54%) | 36 (19.67%) | |
| Donor/recipient relationship, n (%) | ||||
| Parent/child | 36 (10.75%) | 15 (10.56%) | 20 (10.93%) | |
| Sibling/sibling | 132 (39.40%) | 62 (43.66%) | 63 (34.43%) | .192 |
| Child/parent | 164 (48.96%) | 65 (45.78%) | 97 (53.00%) | |
| Other | 3 (0.90%) | 0 | 3 (1.64%) | |
| Anti-HLA antibody, n (%) | ||||
| No DSA | 240 (71.64%) | 105 (73.95%) | 128 (69.95%) | |
| Anti HLA class I Ab | 42 (12.54%) | 16 (11.27%) | 24 (13.11%) | .801 |
| Anti HLA class II Ab | 25 (7.46%) | 9 (6.34%) | 16 (8.74%) | |
| Anti HLA class I and II Ab | 28 (8.36%) | 12 (8.45%) | 15 (8.20%) | |
| Acute GVHD grades 2-4, n (%) | ||||
| No | 191 (57.01%) | 90 (63.38%) | 96 (52.46%) | .055 |
| Yes | 144 (42.99%) | 52 (36.62%) | 87 (47.54%) | |
| Chronic GVHD, n (%) | ||||
| No | 290 (86.57%) | 114 (80.28%) | 167 (91.26%) | .005 |
| Yes | 45 (13.43%) | 28 (19.72%) | 16 (8.74%) |
Totals may vary because of missing data.
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CMV, cytomegalovirus; DSA, donor-specific antibody; HCT-CI, hematopoietic cell transplantation–specific comorbidity index; KPS, Karnofsky performance scale.
Ten patients had a follow-up time of <2 years and were disease-free and alive at time of last follow-up, and hence were excluded from the long-term survivor and the short-term disease-free survivor groups.